Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Download PDF Copy

Nov 30 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies. The new data will be featured in two oral presentations and five poster presentations at the 52^nd American Society of Hematology (ASH) Annual Meeting being held December 4-7, 2010 in Orlando, FL.

Details regarding the presentations are listed below, and full abstracts can be accessed from the ASH website at www.hematology.org.

Oral Presentations

CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, Demonstrates Clinical Activity and Pharmacodynamic Effects in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Presenter: Richard R. Furman, M.D., Weill Medical College of Cornell University, New York, NY
Date/Time: Sunday, December 5, 2010; 4:30 p.m., Eastern Time
Location: Orange County Convention Center, Valencia D
Session: CLL - Therapy, Excluding Transplantation: Novel Agents and New Approaches
Abstract number: 55

Phosphoinositide 3-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike cells (NLC), in Chronic Lymphocytic Leukemia

Presenter: Julia Hoellenriegel, Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX
Date/Time: Sunday, December 5, 2010; 5:45 p.m., Eastern Time
Location: Orange County Convention Center, Valencia B/C
Session: CLL - Biology and Pathophysiology, Excluding Therapy
Abstract number: 48

Poster Presentations

Clinical Safety and Activity in a Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Presenter: Brad Kahl, M.D., University of Wisconsin, Madison, WI
Date/Time: Saturday, December 4, 2010; 5:30-7:30 p.m., Eastern Time
Location: Orange County Convention Center, Hall A3/A4
Poster Board: I-757
Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster I
Abstract number: 1777

A Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 Delta, in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory B-Cell Malignancies

Presenter: Ian W. Flinn, M.D., Ph.D., Sarah Cannon Research Institute, Nashville, TN
Date/Time: Sunday, December 5, 2010; 6:00-8:00 p.m., Eastern Time
Location: Orange County Convention Center, Hall A3/A4
Poster Board: II-712
Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster II
Abstract number: 2832

CAL-101, a Potent Selective Inhibitor of the P110 Delta Isoform of Phosphatidylinositol 3-Kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals from the Microenvironment in Cellular Models of Hodgkin Lymphoma

Presenter: Sarah A. Meadows, Calistoga Pharmaceuticals
Date/Time: Monday, December 6, 2010; 6:00-8:00 p.m., Eastern Time
Location: Orange County Convention Center, Hall A3/A4
Poster Board: III-705
Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
Abstract number: 3926

Clinical Pharmacokinetics of CAL-101, a P110 Delta Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration in Healthy Volunteers and Patients with Hematological Malignancies

Presenter: Heather K. Webb, Ph.D., Calistoga Pharmaceuticals
Date/Time: Saturday, December 4, 2010; 5:30-7:30 p.m., Eastern Time
Location: Orange County Convention Center, Hall A3/A4
Poster Board: I-754
Session: Lymphoma - Chemotherapy, Excluding Pre-Clinical Models: Poster I
Abstract number: 1774

The Role of Phosphatidylinositol 3-Kinase-Delta in the Immunomodulatory Effects of Lenalidomide in Chronic Lymphocytic Leukemia